Ras-Targeting Stabilized Peptide Increases Radiation Sensitivity of Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Radiation therapy is a cornerstone cancer treatment, but tumor resistance limits its efficacy.
• The Ras signaling pathway is implicated in regulating tumor sensitivity to radiation.
• Developing strategies to overcome radiation tolerance is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To design and evaluate novel stabilized peptides targeting the Ras signaling pathway as potential radiosensitizers.
• To assess the binding affinity, cellular uptake, and efficacy of these peptides in enhancing radiation sensitivity in cancer cells.

Main Methods:

• Design and synthesis of Ras-targeting stabilized peptides using an N-terminal nucleation strategy.
• Determination of binding affinity (K_D) to HRas and assessment of cellular uptake.
• Evaluation of peptide H5's effect on ERK phosphorylation and radiosensitivity in HeLa cells, including clonogenic survival assays.

Main Results:

• Developed stabilized peptides with significant binding affinity to HRas (K_D = 0.13 μM) and good cellular uptake.
• Peptide H5 demonstrated inhibition of downstream ERK phosphorylation.
• Peptide H5 significantly increased radiosensitivity in HeLa cells, leading to reduced clonogenic survival.

Conclusions:

• Stabilized Ras-targeting peptides represent a promising new class of radiosensitizers.
• This study demonstrates the potential of these peptides to overcome tumor radiation tolerance.
• The findings broaden the application of stabilized peptides in cancer therapy and radiation oncology.